Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.,Cancer Communications

当前位置： X-MOL 学术 › Cancer Commun. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.
Cancer Communications ( IF 20.1 ) Pub Date : 2020-05-21 , DOI: 10.1002/cac2.12032
Zongbi Yi ₁ , Fei Ma ₁ , Guohua Rong ₁ , Yanfang Guan ₂ , Chunxiao Li ₃ , Binghe Xu ₁

Affiliation

TP53 mutations are common in breast cancer. There is currently no large‐scale cohort study to investigate the TP53 landscape in breast cancer patients from China. The predictive value of TP53 mutations for the efficacy of human epidermal growth factor receptor 2 (HER2)‐targeted therapy in breast cancer remains controversial. In the present study, we aimed to analyze the clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA (ctDNA) from breast cancer patients in China.

更新日期：2020-05-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文